Enhancing dopamine treatments: worth the effort?

作者: Naveed M Malek , Donald G Grosset

DOI: 10.2217/NMT.12.36

关键词:

摘要: SUMMARY Dopamine-based treatments underlie our current management of the motor symptoms Parkinson’s disease. In this article, we look at development levodopa therapy, combination therapies with levodopa/dopa decarboxylase inhibitors, use dopamine agonists, monoamine oxidase catechol-O-methyl transferase inhibitors and nonoral delivery methods, in particular treatment complications later PD. There are some shortcomings dopamine-based including a limited benefit on non-motor manifestations We conclude by looking themes for future developments to further enhance methods.

参考文章(97)
A. Barbeau, Editorial: Long-term assessment of levodopa therapy in Parkinson's disease Canadian Medical Association Journal. ,vol. 112, pp. 1379- 1380 ,(1975)
R. Gray, S. Patel, N. Ives, C. Rick, C. Jenkinson, K. Wheatley, A. Williams, C.E. Clarke, 1.091 A LARGE RANDOMISED TRIAL ASSESSING QUALITY OF LIFE IN PATIENTS WITH EARLY PD: RESULTS FROM PD MED EARLY Parkinsonism & Related Disorders. ,vol. 18, ,(2012) , 10.1016/S1353-8020(11)70205-X
Fabrizio Stocchi, Olivier Rascol, Karl Kieburtz, Werner Poewe, Joseph Jankovic, Eduardo Tolosa, Paulo Barone, Anthony E Lang, C Warren Olanow, None, Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Annals of Neurology. ,vol. 68, pp. 18- 27 ,(2010) , 10.1002/ANA.22060
Fabian Klostermann, Constanze Jugel, Thomas Müller, Frank Marzinzik, Malnutritional neuropathy under intestinal levodopa infusion Journal of Neural Transmission. ,vol. 119, pp. 369- 372 ,(2012) , 10.1007/S00702-011-0689-3
Robert A. Hauser, Mark F. Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek, Cheryl J. Fitzer-Attas, , Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Movement Disorders. ,vol. 24, pp. 564- 573 ,(2009) , 10.1002/MDS.22402
U. K. Rinne, J. P. Larsen, A. Siden, J. Worm-Petersen, , Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations Neurology. ,vol. 51, pp. 1309- 1314 ,(1998) , 10.1212/WNL.51.5.1309
M. J. Steiger, F. Stocchi, L. Bramante, S. Ruggieri, N. P. Quinn, The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clinical Neuropharmacology. ,vol. 15, pp. 501- 504 ,(1992) , 10.1097/00002826-199212000-00007
Claudia Trenkwalder, Bryan Kies, Monika Rudzinska, Jennifer Fine, Janos Nikl, Krystyna Honczarenko, Peter Dioszeghy, Dennis Hill, Tim Anderson, Vilho Myllyla, Jan Kassubek, Malcolm Steiger, Marco Zucconi, Eduardo Tolosa, Werner Poewe, Erwin Surmann, John Whitesides, Babak Boroojerdi, Kallol Ray Chaudhuri, Recover Study Group, None, Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER) Movement Disorders. ,vol. 26, pp. 90- 99 ,(2011) , 10.1002/MDS.23441
Fulvio Bracco, Angelo Battaglia, Carlos Chouza, Erik Dupont, Oscar Gershanik, Jose Felix Marti Masso, Jean-Louis Montastruc, PKDS009, The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. ,vol. 18, pp. 733- 746 ,(2004) , 10.2165/00023210-200418110-00003